13F Holdings
中文EN

RXST RxSight, Inc.

Ophthalmic Goods · Nasdaq · SEC CIK 1111485 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-14.3%
TTM net income YoY-49.3%
TTM EPS YoY-46.6%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—

Margins

Gross margin76.1%
Operating margin-50.4%
Net margin-43.8%
FCF margin15.3%
EBITDA margin-47.5%

Returns

ROE-20.1%
ROA-16.4%
ROIC (approx.)-22.4%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets25.1%
Debt / equity0.00x
Current ratio4.20x
Interest coverage-4,389.57x

Cash quality & payout

Operating cash flow / net income-0.44x
Accruals ratio-23.7%
Payout ratio—
Capex / revenue4.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$134.48M$139.93M$89.08M$49.01M$22.59M
Cost of revenue$31.47M$40.98M$35.31M$27.68M$18.08M
Gross profit$103.01M$98.94M$53.77M$21.33M$4.52M
R&D expense$38.55M$34.37M$29.05M$25.98M$24.50M
SG&A expense$112.65M$101.43M$74.80M$58.66M$32.80M
Operating income-$48.19M-$36.86M-$50.09M-$63.32M-$52.79M
Interest expense$19,000$21,000$3.31M$4.95M$3.68M
Pretax income-$38.88M-$27.41M-$48.59M-$66.75M-$48.68M
Income tax$66,000$50,000$20,000$9,000$8,000
Net income-$38.94M-$27.45M-$48.61M-$66.76M-$48.69M
EBITDA-$44.92M-$33.28M-$46.01M-$59.43M-$48.81M
EPS (basic)-0.95-0.71-1.41-2.41-3.57
EPS (diluted)-0.95-0.71-1.41-2.41-3.57
Weighted avg. shares (diluted)40.85M38.87M34.46M27.66M13.63M
Balance sheet
Cash & equivalents$19.95M$17.46M$10.40M$12.60M$25.17M
Short-term investments$208.18M$220.52M$117.49M$93.97M$134.97M
Receivables$23.38M$30.05M$20.28M$10.96M$4.86M
Inventory$31.56M$22.01M$17.42M$14.84M$8.03M
Current assets$287.46M$293.82M$168.41M$134.56M$176.29M
PP&E, net$13.06M$12.41M$10.84M$10.14M$11.22M
Total assets$311.81M$318.56M$182.55M$150.16M$192.72M
Current liabilities$26.25M$25.88M$20.90M$17.24M$11.08M
Long-term debt——$0$40.17M$39.76M
Total debt——$0$40.17M$39.76M
Total liabilities$36.13M$37.33M$22.19M$60.26M$54.48M
Shareholders' equity$275.68M$281.24M$160.36M$89.90M$138.24M
Net debt——-$10.40M$27.57M$14.59M
Shares outstanding41.24M40.43M36.14M28.27M27.37M
Cash flow statement
Operating cash flow-$15.51M-$16.95M-$41.59M-$58.85M-$44.71M
Capital expenditure$3.83M$5.44M$4.81M$2.39M$1.94M
Free cash flow-$19.34M-$22.39M-$46.41M-$61.24M-$46.65M
Investing cash flow$16.89M-$99.31M-$22.13M$39.95M-$81.91M
Financing cash flow$1.86M$123.32M$61.52M$6.33M$137.34M
Depreciation & amortization$3.27M$3.58M$4.08M$3.88M$3.98M
Stock-based compensation$31.61M$24.64M$15.75M$11.40M$7.58M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.